Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis.

Abstract

Compared to placebo, denosumab treatment significantly decreased the risk of non-vertebral fracture but increased the risk of SAE related to infection in the postmenopausal women with osteoporosis or low BMD. However, no difference between the safety of denosumab and bisphosphonates was found.